(Q31107099)

28 June 2017

title

Systemic catabolism of Alzheimer's Abeta40 and Abeta42. (English)

1 reference

28 June 2017

0 references

3

Miguel Calero

1 reference

28 June 2017

Jorge Ghiso

1

1 reference

28 June 2017

Marcos Shayo

2

1 reference

28 June 2017

Douglas Ng

4

1 reference

28 June 2017

Yasushi Tomidokoro

5

1 reference

28 June 2017

Samuel Gandy

6

1 reference

28 June 2017

Agueda Rostagno

7

1 reference

28 June 2017

Blas Frangione

8

1 reference

28 June 2017

language of work or name

English

0 references

publication date

20 August 2004

1 reference

Journal of Biological Chemistry

28 June 2017

number of pages

12

1 reference

based on heuristic

inferred from page(s)

published in

1 reference

28 June 2017

volume

279

1 reference

28 June 2017

issue

44

1 reference

28 June 2017

page(s)

45897-45908

1 reference

Amyloidosis and Alzheimer's disease

28 June 2017

cites work

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M407668200

Isolation and quantification of soluble Alzheimer's beta-peptide from biological fluids

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M407668200

Production of the Alzheimer amyloid beta protein by normal proteolytic processing

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M407668200

Characterization of beta-amyloid peptide from human cerebrospinal fluid

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M407668200

Relative abundance of Alzheimer A beta amyloid peptide variants in Alzheimer disease and normal aging

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M407668200

Soluble amyloid beta-protein is a marker of Alzheimer amyloid in brain but not in cerebrospinal fluid.

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M407668200

Vascular disorder in Alzheimer's disease: role in pathogenesis of dementia and therapeutic targets

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M407668200

Human blood-brain barrier receptors for Alzheimer's amyloid-beta 1- 40. Asymmetrical binding, endocytosis, and transcytosis at the apical side of brain microvascular endothelial cell monolayer

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M407668200

Glycoprotein 330/megalin: probable role in receptor-mediated transport of apolipoprotein J alone and in a complex with Alzheimer disease amyloid beta at the blood-brain and blood-cerebrospinal fluid barriers

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M407668200

Clearance of Alzheimer's amyloid-ss(1-40) peptide from brain by LDL receptor-related protein-1 at the blood-brain barrier

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M407668200

Beta-amyloid catabolism: roles for neprilysin (NEP) and other metallopeptidases?

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M407668200

The degradation of amyloid beta as a therapeutic strategy in Alzheimer's disease and cerebrovascular amyloidoses

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M407668200

Partial loss-of-function mutations in insulin-degrading enzyme that induce diabetes also impair degradation of amyloid beta-protein

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M407668200

Differential degradation of amyloid beta genetic variants associated with hereditary dementia or stroke by insulin-degrading enzyme

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M407668200

Alzheimer's soluble amyloid beta is a normal component of human urine

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M407668200

A radioiodinated, intracellularly trapped ligand for determining the sites of plasma protein degradation in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M407668200

The half-life on homologous gamma globulin (antibody) in several species

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M407668200

Targeting small Abeta oligomers: the solution to an Alzheimer's disease conundrum?

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M407668200

Evolution of amyloid: what normal protein folding may tell us about fibrillogenesis and disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M407668200

The Sixth International Conference on Alzheimer's disease, Amsterdam, The Netherlands, July 1998. The amyloid cascade hypothesis debate: emerging consensus on the role of A beta and amyloid in Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M407668200

Protofibrils, the unifying toxic molecule of neurodegenerative disorders?

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M407668200

Water-soluble Abeta (N-40, N-42) oligomers in normal and Alzheimer disease brains.

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M407668200

Oligomerizaiton and fibril asssembly of the amyloid-beta protein.

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M407668200

Morphology and toxicity of Abeta-(1-42) dimer derived from neuritic and vascular amyloid deposits of Alzheimer's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M407668200

Soluble amyloid beta peptide concentration as a predictor of synaptic change in Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M407668200

Soluble pool of Abeta amyloid as a determinant of severity of neurodegeneration in Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M407668200

Clusterin (apoJ) Alters the Aggregation of Amyloid β-Peptide (Aβ1-42) and Forms Slowly Sedimenting Aβ Complexes That Cause Oxidative Stress

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M407668200

Naturally secreted oligomers of amyloid beta protein potently inhibit hippocampal long-term potentiation in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M407668200

Diffusible, nonfibrillar ligands derived from Abeta1-42 are potent central nervous system neurotoxins

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M407668200

Vaccination with soluble Abeta oligomers generates toxicity-neutralizing antibodies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M407668200

Soluble oligomers of beta amyloid (1-42) inhibit long-term potentiation but not long-term depression in rat dentate gyrus.

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M407668200

Zeroing in on the pathogenic form of alpha-synuclein and its mechanism of neurotoxicity in Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M407668200

Vesicle permeabilization by protofibrillar alpha-synuclein is sensitive to Parkinson's disease-linked mutations and occurs by a pore-like mechanism.

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M407668200

Receptor-mediated transport of human amyloid beta-protein 1-40 and 1-42 at the blood-brain barrier.

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M407668200

The pentraxins, C-reactive protein and serum amyloid P component, are cleared and catabolized by hepatocytes in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M407668200

Insulin-degrading enzyme: embarking on amyloid destruction.

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M407668200

Clearance of Desialylated Mouse α-Macroglobulin and Murinoglobulin in the Mouse

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M407668200

A 109-amino-acid C-terminal fragment of Alzheimer's-disease amyloid precursor protein contains a sequence, -RHDS-, that promotes cell adhesion

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M407668200

The alpha5beta1 integrin mediates elimination of amyloid-beta peptide and protects against apoptosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M407668200

The SEC receptor: a possible link between neonatal hepatitis in alpha 1-antitrypsin deficiency and Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M407668200

Role of the proposed serpin-enzyme complex receptor recognition site in binding and internalization of thrombin-heparin cofactor II complexes by hepatocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M407668200

The serpin-enzyme complex receptor recognizes soluble, nontoxic amyloid-beta peptide but not aggregated, cytotoxic amyloid-beta peptide

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M407668200

Specificity in recognition of amyloid-beta peptide by the serpin-enzyme complex receptor in hepatoma cells and neuronal cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M407668200

Neurodegenerative diseases and oxidative stress

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M407668200

Neurotoxic, redox-competent Alzheimer's beta-amyloid is released from lipid membrane by methionine oxidation

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M407668200

Alzheimer's amyloid beta-peptide (1-42): involvement of methionine residue 35 in the oxidative stress and neurotoxicity properties of this peptide

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M407668200

Metalloenzyme-like activity of Alzheimer's disease beta-amyloid. Cu-dependent catalytic conversion of dopamine, cholesterol, and biological reducing agents to neurotoxic H(2)O(2).

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M407668200

Abeta immunization and anti-Abeta antibodies: potential therapies for the prevention and treatment of Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M407668200

A safer vaccine for Alzheimer's disease?

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M407668200

Molecular regulation of copper excretion in the liver

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M407668200

21 January 2018

Identifiers

DOI

10.1074/JBC.M407668200

1 reference

28 June 2017

1 reference